Loading the player...
Neoadjuvant Opportunities in Early, High-Risk Breast Cancer
In the past few years, therapeutic options for early-stage, high-risk breast cancers have shown significant efficacy in preventing recurrence and improving outcomes for many patients. And treatment options continue to expand rapidly.
Recent trials, such as OlympiA, monarchE, and KEYNOTE-522, have shown that the use of targeted therapies and immunotherapy can increase survival in patients with various types of early-stage, high-risk breast cancers, including triple-negative breast cancer.
Although the increase in effective treatment options is much needed and exciting, clinicians are faced with numerous questions about how and when to utilize these therapies most effectively.
Dr Lisa Carey, L. Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at UNC School of Medicine, reports on how advancing treatment options are being integrated into clinical practice and are providing the opportunity to better personalize treatment of high-risk, early breast cancers.
Copyright © 1994-2022 by WebMD LLC
Disclosures:
Lisa Carey, MD, and Neysa Heyward, MD, have disclosed no relevant financial relationships.
Recent trials, such as OlympiA, monarchE, and KEYNOTE-522, have shown that the use of targeted therapies and immunotherapy can increase survival in patients with various types of early-stage, high-risk breast cancers, including triple-negative breast cancer.
Although the increase in effective treatment options is much needed and exciting, clinicians are faced with numerous questions about how and when to utilize these therapies most effectively.
Dr Lisa Carey, L. Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at UNC School of Medicine, reports on how advancing treatment options are being integrated into clinical practice and are providing the opportunity to better personalize treatment of high-risk, early breast cancers.
Copyright © 1994-2022 by WebMD LLC
Disclosures:
Lisa Carey, MD, and Neysa Heyward, MD, have disclosed no relevant financial relationships.